Ecabet

Ecabet

SCHEMBL437091

CC(C)c1cc2c(cc1S(=O)(=O)O)[C@@]1(C)CCC[C@@](C)(C(=O)O)[C@@H]1CC2.[NaH]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.98
OPRK1 P41145 1/20 0.98
MMP3 P08254 7/20 0.62
MMP8 P22894 7/20 0.62
MMP9 P14780 6/20 0.62
KARS1 Q15046 3/20 0.61
RXRA P19793 1/20 0.61
CCNE1 P24864 1/20 0.61
CDK2 P24941 1/20 0.61
RXRB P28702 1/20 0.61
RXRG P48443 1/20 0.61
POLA1 P09884 4/20 0.55
POLB P06746 1/20 0.55
APEX1 P27695 1/20 0.55
PDE4D Q08499 1/20 0.55
LMNA P02545 1/20 0.50
CYP3A4 P08684 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ecabet SCHEMBL10935978 1.00 NR1I2 (0.98) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL7615516 1.00 NR1I2 (0.98) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL10938694 1.00 NR1I2 (0.98) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL17747954 0.99 NR1I2 (0.96) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL6546246 0.99 NR1I2 (1.00) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL29727401 0.99 NR1I2 (1.00) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL373030 0.99 NR1I2 (1.00) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL8614405 0.99 NR1I2 (1.00) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL10937325 0.98 NR1I2 (0.98) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL10938701 0.98 NR1I2 (0.98) NR1I2OPRK1MMP3MMP8MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116903498-A Synthesis method of ecabet sodium 江苏亚邦强生药业有限公司 2023-10-20 CN claimed
CN-219707363-U Sub-packaging equipment for ecabet sodium particles 江苏亚邦强生药业有限公司 2023-09-19 CN claimed
CN-216726940-U Full-automatic oscillation instrument for preparing ecabet particles 江苏亚邦强生药业有限公司 2022-06-14 CN claimed
CN-216709697-U Ultra-precision metering equipment for packaging ecabet sodium particles 江苏亚邦强生药业有限公司 2022-06-10 CN claimed
EP-3773907-A1 METHODS OF DISRUPTING A BIOFILM AND/OR PREVENTING FORMATION OF SAME Yeda Research and Development Co. Ltd (IL) 2021-02-17 EP claimed
US-20210015889-A1 METHODS OF DISRUPTING A BIOFILM AND/OR PREVENTING FORMATION OF SAME YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2021-01-21 US claimed
US-20200325543-A1 DIAGNOSTIC METHOD TOLREMO THERAPEUTICS AG (CH) 2020-10-15 US claimed
EP-3714069-A1 DIAGNOSTIC METHOD Tolremo Therapeutics AG (CH) 2020-09-30 EP claimed
CN-111417730-A Diagnostic method 托雷莫治疗股份公司 2020-07-14 CN claimed
CN-111377836-A Crystal form of ecabet sodium and preparation method thereof 四川科瑞德制药股份有限公司 2020-07-07 CN claimed
CN-1703150-A Low moisture chewing gum GUMLINK AS (DK) 2005-11-30 CN claimed
WO-2005110473-A2 METHODS AND ARTICLES FOR THE DELIVERY OF MEDICAMENTS TO THE EYE FOR THE TREATMENT OF POSTERIOR SEGMENT DISEASES DIRECTCONTACT LLC (US) 2005-11-24 WO claimed
US-20050255144-A1 Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases DIRECTCONTACT LLC 2005-11-17 US claimed
CN-1668206-A Chewing gum having improved release of chewing gum ingredients GUMLINK AS (DK) 2005-09-14 CN claimed
CN-1668207-A Degradable chewing gum polymer GUMLINK AS (DK) 2005-09-14 CN claimed
CN-1668208-A Chewing gum comprising at least two different biodegradable polymers GUMLINK AS (DK) 2005-09-14 CN claimed
CN-1668209-A Biodegradable chewing gum comprising at least one high molecular weight biodegradable polymer GUMLINK AS (DK) 2005-09-14 CN claimed
CN-1596108-A Aqueous ECABET sodium solution preparation TANABE SEIYAKU CO (JP) 2005-03-16 CN claimed
US-20040259905-A1 Aqueous ecabet sodium solution preparation MITSUBISHI TANABE PHARMA CORPORATION (JP) 2004-12-23 US claimed
EP-1430892-A1 AQUEOUS ECABET SODIUM SOLUTION PREPARATION TANABE SEIYAKU CO., LTD. (JP) 2004-06-23 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259905-A1 Aqueous ecabet sodium solution preparation SLC10A2, SI, SLC5A6 NR1I2 3670/4885OPRK1 3169/4885MMP3 3370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.